Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2018 Jun 25;13(6):e0199926. doi: 10.1371/journal.pone.0199926

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study

María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban
PMCID: PMC6016912  PMID: 29940039

The second affiliation for the sixth author is not indicated. Martín Prieto is also affiliated with: CIBEREHD, Instituto Carlos III, Madrid, Spain.

Reference

  • 1.Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, et al. (2017) Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS ONE 12(9): e0184550 https://doi.org/10.1371/journal.pone.0184550 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES